1 / 57

Inflammation and the Spine: Mediators to Modulators

Inflammation and the Spine: Mediators to Modulators. J. Scott Bainbridge, M.D. Denver Back Pain Specialists, LLC www.DenverBackPainSpecialists.com. Overview. Nociceptive vs Neuropathic Pain Vs Inflammatory Pain Lines blurred Stimuli and Mediators of Inflammation Inflammation “soup”

evelynm
Download Presentation

Inflammation and the Spine: Mediators to Modulators

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Inflammation and the Spine: Mediators to Modulators J. Scott Bainbridge, M.D. Denver Back Pain Specialists, LLC www.DenverBackPainSpecialists.com

  2. Overview • Nociceptivevs Neuropathic Pain • Vs Inflammatory Pain • Lines blurred • Stimuli and Mediators of Inflammation • Inflammation “soup” • Multi-level Processing of Pain • Neuro-plasticity • Multi-level modulation of inflammatory response • Treatment Strategies and Options

  3. Objectives • Elucidate evidence for role of inflammation in pain of spinal origin. • Describe chemical pathways, mediators, and pharmacological treatments of inflammation. • List side effects of commonly used anti-inflammatory drugs. • Introduce basis for use of exercise, CAM, mindfulness, nutritional, and other treatments for inflammatory pain.

  4. Disclosure • Principal investor in Nutrakinetics, LLC. • Nutraceutical company with interest in anti-inflammatory products Spouse, Professor Jacquelyn Bainbridge, Pharm.D., involved in team building and distribution of Mona Vie nutritional products

  5. Scholz and Woolf; 2002

  6. Plasticity • Peripheral sensitization • Altered sensory neuron excitability • Wind-up • Central sensitization • Synaptic reorganization • Long term potentiation • Disinhibition • Glial activation

  7. Kwon; 2004

  8. Hall; 2004

  9. Hall and Springer; 2004

  10. Scholz and Woolf; 2002

  11. Kwon et al; 2004

  12. Clinical uses of glucocorticoids • Acute whiplash: + one trial IV • Acute spinal cord inj: + high dose methylprednisolone • IM or PO: negative (spine pain) • Spinal: mixed • Intraoperative (HNP/radic): +

  13. Glucocorticoid Action • Decrease Inflammation • decrease prostaglandin, leukotriene synthesis • decrease PMN migration • Direct Membrane Stabilization • Modulation of Periph Nociceptor Neurons • Mod of Spinal Cord Dorsal Horn Cells • Slight Anesthetic Effect

  14. Pharmacologic Properties of Commonly Used Corticosteroids Relative Potency

  15. Fever Myalgia Malaise Fluid and electrolyte imbalance Hypertension Hyperglycemia Myopathy Ulcers Immunosuppression Behavioral changes Allergic reaction Pituitary-adrenal suppression Abrupt withdrawal after prolonged use: acute adrenal insufficiency Corticosteroid Side Effects

  16. Corticosteroid Side Effects Cardiovascular System • Prolonged Use: hypertension due to  Na+ uptake • Direct effects due to steroid receptors on heart and smooth muscle •  cardiac output and vascular tone

  17. Corticosteroid Side Effects Musculoskeletal • Avascular necrosis • Bone mineral density loss • Muscle weakness and wasting • Case report of steroid myopathy after one epidural injection (Boonen S et al. Br J Rheumatol 1995;34:385-6)

  18. Corticosteroid Side Effects Central Nervous System • Euphoria • Behavioral changes; psychosis • EEG abnormalities •  Excitability of nervous tissue

  19. Corticosteroid Side Effects Gastrointestinal System • Gastric acid secretion •  Risk ulcer especially if on NSAIDs • Fat absorption Endocrine System • ACTH, TSH,  FSH,  Testosterone

  20. Adrenal Suppression Intra-articular glucocorticoid injection • Serum cortisol suppressed at 1 week independent of dose ≥40mg triamcinolone • Duration of local and systemic effect increase with decreased solubility (Armstrong RD et al. Ann Rheum Dis 1981;40:571-4)

  21. Adrenal Suppression Epidural steroid injection (ESI) • Suppresses adrenal function 3 weeks • 25 mg Hydrocortisone/80 or 160 mg Methylprednisolone (Benzon HT. Pain 1986;24:277-95)

  22. Adrenal Suppression ESI • Study of 2 individuals, single dose 160mg methylprednisolone, steroid naive • Complete cortisol suppression 6 days • Incomplete at least 4 weeks • Therefore, epidural dosing similar systemic availability to low daily oral glucocorticoid (Dubois EF et al. Clin Rheumatol 2003;22:12-7)

  23. Osteocalcin Depression with Oral Prednisone Wilson AM et al. Chest 1998;114:1022-7.

  24. Bone Mineral Density and ESI Does ESI cause bone loss? • Cross-sectional study of relationship between cumulative ESI dose and BMD • Inconclusive dose relationship • Osteoporosis/osteopenia higher than general population • Could be that all doses caused decreased BMD (Dubois EF et al. Clin Rheumatol 2003;22:12-7)

  25. Bone Mineral Density and ESI • Prospective study 204 patients, 123 follow-up at one year • No change in BMD after standard doses spinal steroids • All spinal injections included • DXA at forearm • Calcium/Vit D ? (Manchikanti L. Pain Physician 2000 Oct;3(4):357-66)

  26. Bone Mineral Density and ESI If ESI = 10-20mg PO x 4 weeks, THEN: • ACR 2001 update for oral steroids • Ca++/Vit D all starting low/moderate dose • Bisphosphonates ≥ 5mg/day for > 3 mo • Bisphosphonates ≥ 5mg/d long term with osteoporosis or osteoporotic fracture

  27. Local Anesthetics Hematologic effects • Epidural inhibit platelets, fibrinolysis, and leukocyte function • ↓ Granulocyte migration /metabolic activation at surgical sites (Naguib M et al. Drug Safety 1998 Apr; 18(4)221-50)

  28. Local Anesthetics Tissue Effects • Cytotoxic to chondrocytes • Bupivicaine 0.5%, 15-30 min in vitro • Intact cartilage provided partial protection (Chu CR et al. Arthroscopy 2006; 22:693-9) • Inhibit Fibroblasts • Myotoxic (Hogan Q. Regional Anesthesia 1996;21:43-50)

  29. Local Anesthetics Neural Toxicity • Intrathecal lidocaine more neurotoxic than epidural • Dose-dependent toxicity found in rats • Doses studied much higher than those used in humans (Kirihara Y et al. Anesthesiology 2003;99:961-8)

  30. Local Anesthetics Overall safety • Large scale surveys attest to overall safety of spinal anesthetics (Hodgson P et al. Anesth Analg 1999;88:797-809)

  31. Tumor Necrosis Factor (TNF-α) • TNFa is a principal mediator of acute inflammatory responses • Macrophages: primary source • Mediator of inflammation, tissue destruction, and organ injury • Lipopolysaccharide is a strong inducer of TNF-α release from macrophages • Homotrimer structure (3 protein chains) • Membrane-bound and soluble forms of TNF-α

  32. NSAID’s • Good evidence for efficacy in acute or episodic back pain

  33. NSAID Cardiovascular Toxicity • Nonselective NSAIDs as a class associated with increased risk of acute MI • Relative risk 1.19, 95% CI 1.08-1.31 • This meta-analysis limited by heterogeneity

  34. NSAID Gastrointestinal Toxicity • 1.3-1.6% annual risk of hospitalization or death due to NSAID-associated gastropathy • 1 in 3 RA patients over course of disease • Long-term NSAID users: • 10% Nonspecific dyspepsia • 1-10% Serious GI bleeding or ulceration • < 1% Kidney toxicity and others

  35. NSAIDs Renal Toxicity • Aspirin doses as low as 75 mg/day may still have adverse renal effects • Study of elderly patients given aspirin 75 mg/day for 1 week, 150 mg/day for 1 week, 325 mg/day for 1 week, then no aspirin for 1 week • All aspirin doses reduced creatinine clearance and uric acid secretion, especially in patients with low albumin levels or taking diuretics • Risk of NSAID toxicity increased with diminished renal function or decreased effective intravascular volume due to diuretic therapy, cirrhosis, or congestive heart failure

  36. NSAIDs and Pregnancy • NSAIDs may be associated with increased risk for miscarriage • Association of NSAIDs with miscarriage based on prescription use of NSAIDs in 63 (1.5%) of 4,268 women who had a miscarriage and 318 (1.5%) of 21,750 women who had a live birth which shows no significant difference but there were significant differences in subgroups when accounting for use of NSAIDs in the preceding 1-9 weeks • In utero exposure to analgesics may be associated with increased risk of developing schizophrenia • Large cohort study found > 4 times increased risk of schizophrenia in persons with analgesic exposure during second trimester • Use of NSAIDs during third trimester may cause premature closure of ductus arteriosus and persistant pulmonary hypertension; uncommon if drug discontinued 6-8 weeks before delivery • Use of NSAIDs during third trimester may cause premature closure of ductus arteriosus and persistant pulmonary hypertension; uncommon if drug discontinued 6-8 weeks before delivery

  37. Other NSAID ADRs • CNS changes (dizziness, aseptic meningitis) • Hepatotoxicity (especially with diclofenac) • Severe rashes (e.g., Steven Johnson’s Syndrome)

  38. Nutrients/Supplements • Anti-oxidants • Anti-inflammatory (COX inhibition or other mechanisms)

More Related